/
HRMY
$38.50-$1.27 (-3.19%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.3B
58M shares
52-week range
$25.52 – $40.87
85% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$6.99
Harmony Biosciences Holdings, Inc. Common Stock
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
www.harmonybiosciences.com- Employees
- 293
- IPO / List date
- Aug 19, 2020
- HQ
- PLYMOUTH MEETING, PA
Held by traders on TradeandTell
No one on the platform currently holds HRMY.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,077,371 | $30.2M |
| Bridgewater Associatesas of 2026-03-31 | 251,506 | $7.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded HRMY yet.
